Northfield Laboratories Inc., bleeds

Northfield released its financial results for the fourth fiscal quarter and year-ended May 31, 2007, informing shareholders that it lost 24 cents a share in the 4th quarter and $1.03 for fiscal 2007. Plans are in place for 2008 . . .

"Our singular focus in FY08 is the successful submission of a Biologics License Application for PolyHeme® with a request for priority review," said Steven A. Gould, M.D., Chairman and Chief Executive Officer. "We have already submitted a detailed summary of the pivotal Phase III trial data to FDA, which was followed by a pre-BLA meeting. Given our strong belief in PolyHeme's ability to address a critical unmet medical need and its potential to save lives, we are committed to making our product available for patients with urgent, life-threatening blood loss when blood is not available."

Northfield's press release included summary coverage of topics listed below (and others):

Highlights of the Year and Upcoming Events
Commercialization Activities
Financial
Investor Outreach
Annual Meeting of Stockholders

I am looking forward to the day when Rambus Inc. provides its shareholders with a date for its annual meeting and shares similar information . . .

Northfield Laboratories - PR machine

Earlier this week Northfield Laboratories took a hit when Morgan Joseph decided to initiate coverage with a "sell" and a $6.00 target.

Today Northfield announces that Steven A. Gould, M.D., Chairman and Chief Executive Officer, will be presenting at the BMO Focus on Healthcare 2006 Conference on Wednesday, December 6, 2006, at 2:30 p.m. ET.

Positive press. Coincidence or public relations department on their game? Whatever, Rambus Inc. should be taking notes.

Northfield Laboratories is a sell?

That is what Morgan Joseph is telling its fans.

Morgan Joseph commenced coverage of Northfield Laboratories with a Sell rating aimed at $6.

StreetInsider.com reports that Morgan Joseph commenced coverage of Northfield Laboratories (Nasdaq: NFLD) with a Sell rating aimed at $6.

Analyst Eugene Trogan said, "PolyHeme Phase III data is likely to be mired by safety concerns, making FDA approval highly unlikely, in our opinion. Questions over PolyHeme's safety have created a climate in which the FDA will feel hard-pressed, in our view, to approve PolyHeme unless the product demonstrates stellar results, a scenario we consider to be highly unlikely. The most well-known risk is hemoglobin's vasoconstrictive effects, among others, some of which include cardiac and gastroinstestinal toxicity, inflammation, and oxidative stress."

Northfield Laboratories which closed yesterday (11/27/06) at $15.64 and opened this morning at $14.90, must be thrilled that Morgan Joseph joined the party.